Mitral regurgitation:
Treatment is complex and options are limited

Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected1

Medically managed patients with severe MR have poor outcomes2

Mitral regurgitation

Transform the way you see mitral valve repair

Empowering


Optimised leaflet
capture

  • Empowering delivery system with direct manoeuvring in 3 planes
  • Independent leaflet capture

Effective


Designed for effective MR
reduction

  • Broad paddles maximize leaflet coaptation
  • Central spacer fills the regurgitant orifice area

Safe


Excellent safety
profile

  • Spacer & contoured paddle design reduce stress on leaflets
  • Implant elongation helps promote safe subvalvular manoeuvring
Optimised leaflet capture

Empowering PASCAL delivery system with direct manoeuvring in 3 planes to improve procedural efficiency

Optimised leaflet capture

Broad paddles create a wide area for simplified leaflet capture


Independent leaflet capture supports gentle interaction and enables operators to capture leaflets in difficult pathologies

Designed for effective mitral regurgitation reduction3

Configuration delivers desired outcomes while respecting native anatomy

Excellent safety profile

Contoured paddles and a unique central spacer are designed to reduce leaflet stress while implant elongation helps promote safe subvalvular manoeuvring

Excellent safety profile

See how it works

Watch the PASCAL repair system procedural animation

Learn more about Edwards' transcatheter mitral
and tricuspid portfolio
Register for PASCAL repair system updates

Sign up now to receive event and news information from Edwards Lifesciences including:

  • Publications
  • Congress highlights
  • Webinar invites
  • Product announcements and updates
References:
  1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
  2. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-186.
  3. Praz F, Spargias K, Chrissoheris M et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017;390(10096):773-780.

For professional use

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

For professional use

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Material for distribution only in countries with applicable health authority product registrations. Material not intended for distribution in USA or Japan.

Edwards, Edwards Lifesciences, the stylized E logo, PASCAL, and Cardioband are trademarks of Edwards Lifesciences .Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved. E8827/02-19/TMTT

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com

Please update your browser

Please update to a current version of your preferred browser, this site will perform effectively on the following:

Unable to update your browser?

If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility